close
MENU
2 mins to read

'Phenomenal' opportunity in drug market, Biomatters says

The Auckland-based company has a new product to help big pharma develop biological drugs.

Calida Smylie
Wed, 19 Apr 2017

Auckland-based tech company Biomatters has designed cloud-based software to be used by biopharma companies developing biological drugs.

The 13-year-old company, which already has a genetic code data analysis tool called Geneious in the market, launches its new product Geneious Biologics next

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Calida Smylie
Wed, 19 Apr 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
'Phenomenal' opportunity in drug market, Biomatters says
66398
true